This trial is evaluating whether Experimental: Tezepelumab will improve 6 secondary outcomes and 10 other outcomes in patients with Sinusitis. Measurement will happen over the course of Baseline to Week 52.
This trial requires 400 total participants across 2 different treatment groups
This trial involves 2 different treatments. Experimental: Tezepelumab is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"Sinusitis is a common complaint and is treatable. The primary treatment used for symptoms is anti-allergic and anti-inflammatory medications such as the antihistamines, leukotriene receptor antagonists, and steroids. The common surgery performed on the nose included septoplasty and turbinate reduction, septorhinoplasty, and laceration repair of a persistent tear." - Anonymous Online Contributor
"There was no evidence that the sinusitis was cured after two months of antibiotics in this study. The authors recommend repeated evaluations without cure to exclude relapse." - Anonymous Online Contributor
"Signs and symptoms of nasal obstruction appear about 1-2 weeks before the onset of fever or nasal discharge. People with sinusitis tend to have headache, a runny nose and a general feeling of flu-like symptoms including fatigue or muscle aches." - Anonymous Online Contributor
"There is no single known cause of sinusitis. The vast majority of cases are due to bacteria colonising tissues, although viral infections, chemical irritation and airway inflammation can contribute additional factors. Prevention is likely to be through better airway management (cleanliness and hygiene) and improvement in socioeconomic factors such as increased cleanliness." - Anonymous Online Contributor
"More than half (53%) of the U.S. population has at least a one sinusitis infection a year, and this could lead to significant and troubling health consequences. One of the challenges to improving clinical care for patients with sinusitis is to understand how the general population is affected by sinusitis. This report may help in this regard." - Anonymous Online Contributor
"Most common diseases in pediatric ENT are bacterial infections, with sinusitis being the most common presentation. The majority of pediatric ENT cases are caused by viral triggers. In children and teenagers, rhinovirus and respiratory syncytial virus are most common causes of viral infections. In more than two thirds of all children with sinusitis, an allergy is confirmed. There is substantial overlap in signs and symptoms between infectious and allergic causes." - Anonymous Online Contributor
"The main cause of sinusitis is nasal obstruction (65.2%); other causes are viral (15.5%), bacterial (9.3%), fungal (4.7%) and parasitic (4.7%) respectively. Sinusitis occurs commonly in all age groups and in both sexes. In children there is more sinonasal involvement." - Anonymous Online Contributor
"To treat sinusitis, it is important to choose the correct antibiotics and use them correctly (according to patient age, the patient's general condition and any changes or side effects the patient might have). question: Does naltrexone treatment in rats attenuate ethanol-induced conditioned place preference in an inverse dose-response relationship? answer: The inverse dose-response relationship between conditioned place preference and absolute ethanol self-administration seen in untreated rats is in sharp contrast with the more usual positive relationship between ethanol self-administration in the rat and conditioned place preference. These data suggest a possible relationship between pharmacologic inhibition of NMDA receptor transmission with ethanol self-administration, and with the development of alcohol intake." - Anonymous Online Contributor
"In patients with active moderate-to-severe sinusitis treated in clinical equivalence trials, treatment with TEz improves sinus inflammation and symptoms of quality of life but does not affect lung function." - Anonymous Online Contributor
"There was no evidence for efficacy in tezepelumab arms, especially among patients with moderate-to-severe disease, who were predominantly receiving corticosteroid therapy but who responded to corticosteroid therapy in a subset of patients. Atezepelumab may be safe, but it is not effective." - Anonymous Online Contributor
"Tezepelumab is well tolerated by people with moderate to severe active chronic rhinosinusitis undergoing regular rhinosinusitis surgical intervention. Tolerance to nasal symptoms improved significantly during the study. There was no increase in serious adverse events in this group; however, further data are required to confirm these findings." - Anonymous Online Contributor
"The study suggests that the experimental therapy was more effective than the placebo in people with moderate-to-severe CRSwNP. There were no serious adverse events. We did not find evidence of an increase in the risk for infection or a serious adverse effect." - Anonymous Online Contributor